- Home
- ISOU vs PRTA Comparison
ISOU vs PRTA Comparison
Compare ISOU & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ISOU | PRTA |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | Canada | Ireland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 501.4M | 538.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ISOU | PRTA |
|---|---|---|
| Price | $10.44 | $8.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.86 |
| AVG Volume (30 Days) | 166.1K | ★ 500.4K |
| Earning Date | 02-26-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,786,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,183.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.52 | $4.32 |
| 52 Week High | $13.58 | $16.67 |
Technical Indicators
Market Signals| Indicator | ISOU | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 46.66 | 44.32 |
| Support Level | $9.33 | $8.23 |
| Resistance Level | $12.22 | $9.05 |
| Average True Range (ATR) | 1.05 | 0.53 |
| MACD | -0.31 | -0.05 |
| Stochastic Oscillator | 25.41 | 26.96 |
Price Performance
Historical ComparisonAbout ISOU IsoEnergy Ltd.
IsoEnergy Ltd is engaged in the acquisition, exploration, and evaluation of uranium properties in Canada. The company's project profile includes Thorburn Lake, Radio, Geiger, and Larocque East. and others. It operates in Canada, the United States, and Australia.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.